O.
Pfaar
Publicacións nas que colabora con O. Pfaar (10)
2021
-
A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial
Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 3, pp. 1020-1030.e10
-
Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 4, pp. 1041-1052
-
Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 629-647
2019
-
Comparison of International Systemic Adverse Reactions Due to Allergen Immunotherapy
Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 4, pp. 1298-1305.e3
2018
-
Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 4, pp. 827-836
2017
-
European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, Núm. 3, pp. 462-472
-
The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment
Pediatric Allergy and Immunology, Vol. 28, Núm. 1, pp. 60-70
2016
-
Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies
Clinical and Translational Allergy, Vol. 6, Núm. 1
2014
-
An EAACI "european Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)": The methodology
Clinical and Translational Allergy, Vol. 4, Núm. 1
2012
-
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy
Clinical and Translational Allergy, Vol. 2, Núm. 1